Fair Value Measurements - Narrative (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost share advance	$ 33,818,000	$ 121,862,000	$ 0
Fair Value, Nonrecurring
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total assets	$ 0	0
Pfizer | Level 2
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost share advance		$ 146,400,000